Shots:
- The launch of Tacrolimus capsules follows the approval of the US FDA in Nov’20 and emphasizes Biocon activity to make affordable healthcare accessible
- Tacrolimus is particularly effective in treating patients of renal transplant
- Tacrolimus, a calcineurin inhibitor immunosuppressant used to treat organ transplant patients, reduces the body’s ability to reject a transplanted organ
Click here to read full press release/ article | Ref: Biocon | Image: Business Standard
The post Biocon has Launched Tacrolimus Capsules in the US first appeared on PharmaShots.
